Posted On: 01/16/2016 4:02:59 PM
Post# of 30066
"Mr. Commissiong will discuss details regarding a pending Amarantus Diagnostics, Inc. spin-out transaction into a publicly-traded, immuno-oncology-focused diagnostics company."
I don't really know what he could say without breaching Regulation FD. "Details" would seem to be material information that all investors would be entitled to hear.
"Immuno-oncology" refers to using using the body’s immune system to fight cancer. That not Lympro or MSPrecise.
So it must mean that the spin-out involves another company - an immuno-oncology-focused diagnostics company. That's the speculation on twitter today.
I don't really know what he could say without breaching Regulation FD. "Details" would seem to be material information that all investors would be entitled to hear.
"Immuno-oncology" refers to using using the body’s immune system to fight cancer. That not Lympro or MSPrecise.
So it must mean that the spin-out involves another company - an immuno-oncology-focused diagnostics company. That's the speculation on twitter today.
Quote:
Scooter @ScottGlibowski 5 hours ago
@rocco74p we are in middle of closing on the purchase of an immuno oncology revenue producing dx company!! $ambs
(0)
(0)
